Evidence map›Paper›PMID 38687064›Full record

ArticleMicrobiology spectrum2024

An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection.

Carly G K Ziegler, Anna H Owings, Michelle Galeas-Pena, Samuel W Kazer, Vincent N Miao, Andrew W Navia, Ying Tang, Joshua D Bromley, Peter Lotfy, Meredith Sloan and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Carly G K Ziegler *Program in Health Sciences & Technology, Harvard Medical School & MIT, Boston, Massachusetts, USA.
Anna H Owings *Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Michelle Galeas-PenaDepartment of Medicine, Section of Gastroenterology and Hepatology, Tulane University School of Medicine, New Orleans, Los Angeles, USA.ORCID 0000-0002-9257-3222
Samuel W KazerProgram in Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Vincent N MiaoProgram in Health Sciences & Technology, Harvard Medical School & MIT, Boston, Massachusetts, USA.
Andrew W NaviaRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Ying TangDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
Joshua D BromleyRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Peter LotfyBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Meredith SloanDepartment of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Hannah LairdDivision of Digestive Diseases, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Haley B WilliamsDivision of Digestive Diseases, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Micayla GeorgeRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Riley S DrakeRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Yilianys PrideDivision of Digestive Diseases, University of Mississippi Medical Center, Jackson, Mississippi, USA.
George E AbrahamDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Michal SenitkoDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Tanya O RobinsonDivision of Digestive Diseases, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Gill DiamondDepartment of Oral Immunology and Infectious Diseases, University of Louisville, Louisville, Kentucky, USA.
Michail S LionakisFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA.ORCID 0000-0003-4994-9500
Alex K Shalek *Program in Health Sciences & Technology, Harvard Medical School & MIT, Boston, Massachusetts, USA.ORCID 0000-0001-5670-8778
Jose Ordovas-Montanes *Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0001-5444-5601
Bruce H Horwitz *Program in Immunology, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-8123-8728
Sarah C Glover *Division of Digestive Diseases, University of Mississippi Medical Center, Jackson, Mississippi, USA.ORCID 0000-0002-9899-0473

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel DiseaseRC2DK122532 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI KLEIN, CHRISTOPH, MUISE, ALEIXO M · 2020 to 2024
$9.1M
Initiation of immune responses to SARS COV2 in the oral cavity and upper airwayR01DE031928 · NIDCR · UNIVERSITY OF MISSISSIPPI MED CTR · PI GILL DIAMOND, SARAH C GLOVER · 2022 to 2026
$3.8M
Balancing epithelial cell resistance and resilience to respiratory viral infectionsR01HL162642 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Jose Manuel Ordovas-Montanes · 2023 to 2026
$3.4M
An integrated multiplexed genomic assay for low input clinical samples1U24AI118672 · NIAID · BROAD INSTITUTE, INC. · PI SHALEK, ALEX K · 2015 to 2019
$2.0M
Innate immune mechanisms of periodontal disease and inflammatory bowel diseaseR21DE028378 · NIDCR · UNIVERSITY OF MISSISSIPPI MED CTR · PI DIAMOND, GILL, GLOVER, SARAH C · 2019 to 2020
$436k
Chan Zuckerberg Initiative (CZI) 2020-216949Chan Zuckerberg Initiative (CZI) DAF2021-237665HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) DK122532-01A1, 5U24AI118672HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007753, T32GM144273HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID) R01 HL162642, R01 DE031928NHLBI NIH HHS R01 HL162642NIAID NIH HHS U24 AI118672NIDCR NIH HHS R01 DE031928NIDCR NIH HHS R21 DE028378NIDDK NIH HHS RC2 DK122532NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM008313NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Recent case reports and epidemiological data suggest that fungal infections represent an underappreciated complication among people with severe COVID-19. However, the frequency of fungal colonization in patients with COVID-19 and associations with specific immune responses in the airways remain incompletely defined. We previously generated a single-cell RNA-sequencing data set characterizing the upper respiratory microenvironment during COVID-19 and mapped the relationship between disease severity and the local behavior of nasal epithelial cells and infiltrating immune cells. Our previous study, in agreement with findings from related human cohorts, demonstrated that a profound deficiency in host immunity, particularly in type I and type III interferon signaling in the upper respiratory tract, is associated with rapid progression to severe disease and worse clinical outcomes. We have now performed further analysis of this cohort and identified a subset of participants with severe COVID-19 and concurrent detection of IMPORTANCE: In this paper, we present an analysis suggesting that symptomatic and asymptomatic fungal coinfections can impact patient disease progression during COVID-19 hospitalization. By looking into the presence of other pathogens and their effect on the host immune response during COVID-19 hospitalizations, we aim to offer insight into an underestimated scenario, furthering our current knowledge of determinants of severity that could be considered for future diagnostic and intervention strategies.

Indexed as

CoinfectionCOVID-19Epithelial CellsInterferon Type IInterleukin-17SARS-CoV-2AdultAgedCandidiasisFemaleHumansMaleMiddle AgedMycosesNasal MucosaNasopharynxInterferon Type IInterleukin-17anti-viralCandidaCOVID-19cytokineepithelial immunityfungal infectionhumanIL17interferonnasal mucosaSARS-CoV-2scRNA-seq

Identifiers

PMID38687064
PMCPMC11237666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.